News & Updates
Filter by Specialty:
Metformin plus R-form verapamil improves glycaemic control in T2D
Combination therapy with metformin plus R-form verapamil (R-Vera) leads to significant improvements in glycaemic control by reducing haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) among patients with type 2 diabetes (T2D), reports a study.
Metformin plus R-form verapamil improves glycaemic control in T2D
19 Oct 2022Lenvatinib-pembrolizumab combo fails to spring forward in HCC treatment
In the phase III LEAP*-002 study, a combination regimen comprising lenvatinib and pembrolizumab appeared to have similar efficacy and safety as lenvatinib monotherapy as first-line therapy for advanced hepatocellular carcinoma (HCC).
Lenvatinib-pembrolizumab combo fails to spring forward in HCC treatment
19 Oct 2022Does atezolizumab improve OS in patients with resected NSCLC and PD-L1 ≥1 percent?
The first interim analysis of the phase III IMpower010 trial suggests an overall survival (OS) benefit with atezolizumab compared with best supportive care (BSC) in patients with resected non-small cell lung cancer (NSCLC) with PD-L1* tumour cell expression ≥1 percent.